http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110305965-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-50 |
| filingDate | 2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110305965-B |
| titleOfInvention | A method for predicting the sensitivity of non-small cell lung cancer (NSCLC) patients to immunotherapy |
| abstract | The present invention discloses methods of predicting the sensitivity of a cancer (non-small cell lung cancer) patient to immunotherapy, for example immunotherapy with immune checkpoint inhibitors, using two genes, KMT2C and TP53 as biomarkers; also disclosed is the use of an agent that specifically detects the biomarker for the manufacture of a kit for predicting the sensitivity of a cancer patient (non-small cell lung cancer) to immunotherapy, for example immunotherapy using an immune checkpoint inhibitor. In the invention, TP53 and KMT2C gene mutation states are considered in a combined manner, so that a population sensitive to ICI in NSCLC patients can be accurately predicted, blind medication is avoided, and the economic performance of ICI treatment is improved. |
| priorityDate | 2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.